Healthcare -
Biotechnology - NASDAQ - US
$ 67.08
-9.6 %
$ 4.82 B
Market Cap
-17.35
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Nuvalent, Inc.
| Net Income | -261 M |
| Depreciation & Amortization | -58.7 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 60.6 M |
| Change in Working Capital | 11.8 M |
| Others | 19.2 M |
| Free Cash Flow | -185 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (260.8) | (126.2) | (81.9) | (46.3) | (14.6) | (11.8) |
| Depreciation & Amortization | 0 | 0 | (0.4) | 0.2 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | (5.7) | (0.2) | 0 | 0 |
| Stock Based Compensation | 60.6 | 25.6 | 10.3 | 3.6 | 0.7 | 41 K |
| Other Operating Activities | 3.3 | (10.1) | 5.7 | 0.8 | (2.4) | 1.6 |
| Change in Working Capital | 11.8 | 11.0 | 6.9 | 1.9 | 1.3 | 0.6 |
| Cash From Operations | (185.1) | (99.7) | (65.0) | (40.0) | (14.9) | (9.6) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Items | (573.5) | (143.5) | (10.7) | (220.0) | 0 | 0 |
| Cash From Investing Activities | (573.5) | (143.5) | (10.7) | (220.0) | 0 | 0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0.3 | 22.2 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.1) | 12.5 | 0.3 | 140.7 | 15 K | 0 |
| Cash From Financing Activities | 568.9 | 336.8 | 248.9 | 318.2 | 22.3 | 0 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (189.7) | 93.6 | 173.3 | 58.2 | 7.3 | (9.6) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (185.1) | (99.7) | (65.0) | (40.0) | (14.9) | (9.6) |